Echo Therapeutics, creator of a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system called Symphony and a transdermal drug delivery system called Prelude SkinPrep, recently debuted a demonstration video on its company website, reports MedGadget. The new video showcases the use of the Symphony system in a home setting and coincides with an upcoming clinical study.

The video displays how the needle-less system works. The skin is permeated with the Prelude SkinPrep, and a biosensor is placed on the permeated site. The Symphony system then wirelessly provides the patient's glucose level each minute to a remote monitor, which tracks glucose levels and glucose changes and provides visual and audible alarms if the patient's levels move outside a personalized target range.

"We are excited to feature the demonstration video on our website in order to illustrate the ease of using Symphony," stated Echo Therapeutics CEO Patrick T. Mooney in a press release. "We believe that Symphony will be an important and differentiated candidate for glucose monitoring that has the potential to change the paradigm of invasive, episodic glucose monitoring."

You can read the MedGadget article here.